Here is the design of a clinical trial:

Official Title: Efficacy of Self-management of Sedative Therapy by Ventilated ICU Patients

Included conditions:
- Critical Illness
- Anxiety
- Respiratory Failure

Study Armgroups:
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team'}
- {'label': 'Dexmedetomidine', 'type': 'EXPERIMENTAL', 'description': 'These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.', 'interventionNames': ['Drug: Dexmedetomidine']}

Interventions:
- {'type': 'DRUG', 'name': 'Dexmedetomidine', 'description': 'Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.', 'armGroupLabels': ['Dexmedetomidine'], 'otherNames': ['Precedex']}

Primary Outcomes:
- {'measure': 'Changes in anxiety using the 100mm vertical visual analog scale', 'description': 'Vertical visual analog scale will be used to measure level of state anxiety', 'timeFrame': '7 days'}
- {'measure': 'Changes in duration of days receiving mechanical ventilation after study enrollment', 'description': "Patients' self-management of sedative therapy (SMST) using dexmedetomidine compared to usual sedation practices in mechanically ventilated subjects.", 'timeFrame': 'up to 6 months'}
- {'measure': 'Changes in delirium using the CAM-ICU tool', 'description': 'Confusion Assessment Method-ICU (CAM-ICU) will be used as a pre-enrollment delirium screening tool and to measure level of alertness and presence of delirium', 'timeFrame': '7 days'}

Please estimate the sample size based on the assumption: 
The significance level (alpha) is set at 0.05, and the power is greater than 80%. The study design includes a minimum of 7 data collection points per patient, resulting in approximately 1050 observations.
Sample size {14}
          Our primary outcomes are anxiety, duration of mechanical ventilation, and presence of delirium. Each primary outcome is analysed separately. In our preliminary study [18], anxiety decreased over time for the experimental self-management of sedative therapy group by 5 points from 58.1 to 53.1 (0â100 mm visual analogue scale), whereas it increased by 15.5 points from 43.7 to 53.9 for the control group. The calculated delta change for anxiety = .45 for an effect size = .11 with a sample size of 95 per group (190 total). We base our target sample size on these anxiety data for this efficacy RCT. During the pilot RCT, no patients randomized to the experimental group became delirious, while four patients randomized to the control group developed delirium (p = .058). A sample of 35 subjects per group would be required (70 total). The power calculation for the duration of mechanical ventilatory support after study enrolment (Mann-Whitney U) with an effect size of .41 would = 43 per group (86 total). We estimated the power for multilevel models approximating our study design. A sample size of 95 patients per arm, 190 total (at a minimum of 7 data collection points for each, resulting in ~ 1050 observations) will have greater than 80% power to detect small to moderate effects (i.e. 0.11 or greater) in between-group differences in anxiety, delirium, and duration of mechanical ventilation at alpha = .05 for all proposed models.